Height protein could be cancer and diabetes treatment target

May 16, 2014 by Bronwyn Adams
Height protein could be cancer and diabetes treatment target
Dr Andrew Brooks and Professor Mike Waters

University of Queensland scientists have discovered that a protein that regulates how tall you grow could be used in treating diseases including cancer and diabetes.

Growth hormone, acting through its receptor, determines whether you are struggling to reach high shelves or bumping your head on doorways.

Researchers from UQ's Institute for Molecular Bioscience, led by Professor Mike Waters, have now found it is also an untapped target for drugs.

"People without don't die from cancer or diabetes, making it an ideal drug target," Professor Waters said.

"But we didn't know enough about how it functioned to be able to design cancer or that would bind to the receptor and turn it either on or off as appropriate.

"We've now figured out how growth hormone turns on its receptor at the molecular level, and so have a clear idea of which part of the molecule to target to design drugs to combat these diseases."

This is the culmination of 45 years of work studying growth hormone for Professor Waters, who originally cloned the receptor with Genentech, one of the world's leading biotechnology companies.

The discovery was published overnight in Science.

Dr Andrew Brooks, who led the study with Professor Waters, said the discovery had implications beyond cancer and diabetes.

"Growth is one of a group of proteins known as cytokine receptors, which are important targets for therapeutics for a range of disorders, including , blood disorders, osteoporosis and obesity," Dr Brooks said.

"Our understanding of how receptor functions should give us insights into how the other cytokine receptors work, which in turn will inform the design of therapeutics to target these cytokine receptors and to treat many diseases."

Explore further: Growth hormone could promote cancer, according to new research

More information: Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor, Science, 2014.

Related Stories

Structural biology spin-out tackles major diseases

August 7, 2008

A spin out company from basic structural biology, Asterion Ltd., has led to new technology that provides a way of creating therapeutic proteins to tackle major diseases such as cancer, diabetes and infertility. The research ...

Target for obesity drugs comes into focus

October 11, 2012

(Medical Xpress)—Researchers at the University of Michigan have determined how the hormone leptin, an important regulator of metabolism and body weight, interacts with a key receptor in the brain.

Recommended for you

Basic research fuels advanced discovery

August 26, 2016

Clinical trials and translational medicine have certainly given people hope and rapid pathways to cures for some of mankind's most troublesome diseases, but now is not the time to overlook the power of basic research, says ...

New method creates endless supply of kidney precursor cells

August 25, 2016

Salk Institute scientists have discovered the holy grail of endless youthfulness—at least when it comes to one type of human kidney precursor cell. Previous attempts to maintain cultures of the so-called nephron progenitor ...

New avenue for understanding cause of common diseases

August 25, 2016

A ground-breaking Auckland study could lead to discoveries about many common diseases such as diabetes, cancer and dementia. The new finding could also illuminate the broader role of the enigmatic mitochondria in human development.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.